A randomized, double-blind, multi-center, therapeutic confirmatory study to evaluate the effectiveness(immunogenicity) and safety of `GC501(influenza split vaccine)' administered intramuscularly in healthy adults

Trial Profile

A randomized, double-blind, multi-center, therapeutic confirmatory study to evaluate the effectiveness(immunogenicity) and safety of `GC501(influenza split vaccine)' administered intramuscularly in healthy adults

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Green Cross
  • Most Recent Events

    • 30 Aug 2011 Actual initiation date 3 Jul 2008 added as reported by Korean Clinical Trials Register.
    • 26 Aug 2011 New source identified and integrated (Korean Clinical Trials Register).
    • 19 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top